← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 2
Neoadjuvant chemotherapy (Neoadjuvant chemotherapy)
Sanofi·Breast Cancer
ORR 24%
Overview
Program
Neoadjuvant chemotherapy
Overview
Company
Sanofi
Overview
Modality
ANTIBODY
Overview
Target
Breast Cancer
Overview
Indication
Colonic Neoplasms
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
MoA
Mechanism
ADCmin value, Ki-67 index, tumor size, clinical N stage, and HR status as independent predictors
MoA
Biomarker
EGFR2 expression
PK/PD
Species
Mouse, Human
PK/PD
Animal (cat.)
Human, Mouse
PK/PD
Experiment
PD
Toxicology
Species
Mouse, Human
Toxicology
Animal (cat.)
Human, Mouse
Toxicology
Major finding
Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage.. Metal (MS) or plastic stents (PS) are placed for preoperative biliary drainage (PBD) in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemotherapy (NAC) or chemoradiotherapy (NACRT). This multicentre retrospective study compared the safety and efficacy o…
Clinical
Primary efficacy
ORR 24%
Clinical
ORR
24%
Clinical
OS
24.1
Clinical
Result source
ClinicalTrials.gov NCT00193128
Clinical
Data Tier / Score
A · 43
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 12일 (2일 전)